Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Purpose: Prior progestin studies treating hot flashes in women have been short duration and single dose. This study tests the progestin megesterol acetate (MA) at two doses versus placebo over 6 months. Patients and Methods: Patients with T1-3, N0-1, M0 breast cancer were eligible after completion of surgery and chemotherapy and at least 4 months of tamoxifen (if prescribed). Women were required to have at least 10 hot flashes of any severity or at least five severe episodes per week. Patients were randomly assigned to placebo, MA 20 mg, or MA 40 mg for 3 months. Success at 3 months was defined as completion of treatment with a ≥ 75% reduction in hot flashes from baseline. If success was achieved, drug treatment for another 3 months was given on the same blinded arm; if not, open-label MA 20 mg was added to blinded study drug and continued for 3 months. Other menopausal symptoms were also assessed. Results: Two hundred eighty eight eligible women were randomly assigned (286 eligible), of whom 85% were on tamoxifen, 40% had over 63 hot flashes/week, and 75% had vasomotor symptoms for ≥ 6 months. Success at 3 months was 14% on placebo, 65% on 20 mg, and 48% on 40 mg (both MA doses superior to placebo; P < .0001). Most successes at 3 months were maintained at 6 months (77% on 20 mg and 81% on 40 mg). Conclusion: MA significantly reduced vasomotor symptoms with durable benefit over 6 months. MA 20 mg/d is the preferred dose. There was no significant impact on other menopausal symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487 · cited 3×
“24 when progesterones alone were used as HRT.(24) In this study, MA did not impact favorably on menopausal symptoms other than hot flashes.”
MethodInfluentialLoprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Progestin regulation of cellular proliferation.
CLARKE, C. L., & SUTHERLAND, R. L. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-266 · Cited by 650 · cited 1×
“Studies both in vitro and in vivo have demonstrated both stimulating and inhibitory properties of progestins on breast epithelium.(17,18) Data from the Woman’s Health Initiative study and review reports(19-22) demonstrate an increased risk of breast cancer from estrogen plus progesterone as compared with estrogen alon…”
BackgroundMegestrol acetate for the prevention of hot flashes.
Loprinzi, C. L., Michalak, J. C., Quella, S. K., O'Fallon, J. R., Hatfield, A. K., Nelimark, R. A., Dose, A. M., Fischer, T., Johnson, C., Klatt, N. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408113310602 · Cited by 500
Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes
Loprinzi, C. L., Sloan, J. A., Perez, E. A., Quella, S. K., Stella, P. J., Mailliard, J. A., Halyard, M. Y., Pruthi, S., Novotny, P. J., & Rummans, T. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1578 · Cited by 473
Methodologic lessons learned from hot flash studies.
Sloan, J. A., Loprinzi, C. L., Novotny, P. J., Barton, D. L., Lavasseur, B. I., & Windschitl, H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4280 · Cited by 462
Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.
Barton, D. L., Loprinzi, C. L., Quella, S. K., Sloan, J. A., Veeder, M. H., Egner, J. R., Fidler, P., Stella, P. J., Swan, D. K., Vaught, N. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.495 · Cited by 403
Quella, S. K., Loprinzi, C. L., Barton, D. L., Knost, J. A., Sloan, J. A., LaVasseur, B. I., Swan, D., Krupp, K. R., Miller, K. D., & Novotny, P. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1068 · Cited by 372
Cited by
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study
Goldstein, D., Bennett, B. K., Webber, K., Boyle, F., de Souza, P. L., Wilcken, N. R. C., Scott, E. M., Toppler, R., Murie, P., O'Malley, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.6148 · Cited by 140
Chwalisz, K., Surrey, E., & Stanczyk, F. Z. (2012) · Reproductive Sciences · doi:10.1177/1933719112438061 · Cited by 58
“In addition, megestrol acetate, a progestin without any estrogenic activity, is frequently used to manage hot flashes in men with prostate cancer undergoing androgen deprivation therapy and in women with breast cancer who cannot use estrogens.(53,54) These data suggest that there are beneficial effects of progestins o…”
Ramaswami, R., Villarreal, M. D., Pitta, D. M., Carpenter, J. S., Stebbing, J., & Kalesan, B. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3465-5 · Cited by 49
“menopausal symptoms among women with breast cancer [7, 8].”
Background
Metadata
- Authors
- Goodwin, J. W., Green, S. J., Moinpour, C. M., Bearden, J. D., Giguere, J. K., Jiang, C. S., Lippman, S. M., Martino, S., & Albain, K. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-04-01
- Volume
- 26
- Issue
- 10
- Pages
- 1650-1656
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2103075983
- Cited by
- 65
- References
- 12
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626. https://app.cochat.ai/papers/10.1200/jco.2006.10.6179
- The paper
- Goodwin, J. W., Green, S. J., Moinpour, C. M., Bearden, J. D., Giguere, J. K., Jiang, C. S., Lippman, S. M., Martino, S., & Albain, K. S. (2008). Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.10.6179
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.